Ipamorelin CAS:170851-70-4

Ipamorelin is a synthetic peptide that stimulates the natural production of growth hormone in the body. This implicates the peptide in a range of biological processes, including bone formation, muscle growth, and fat loss.

Ipamorelin is a synthetic growth hormone secretagogue (GHS) that stimulates the pituitary gland to release growth hormone (GH), thereby affecting key biological processes like bone health, metabolism, and body composition.

Structurally, it is a pentapeptide composed of five amino acids, and an agonist of the ghrelin receptor (GHSR), which plays a key role in regulating energy homeostasis and body weight.

Ipamorelin was identified in 1998 as the first synthetic GHS to achieve selective GH release, showing a selectivity that was comparable to growth hormone-releasing hormone (GHRH). It was developed by the pharmaceutical company Novo Nordisk and assigned the developmental code name NNC 26-0161.

Subsequently, ipamorelin was notably investigated as a treatment of postoperative ileus, which is characterized by a lack of propulsive ability of the intestine, leading to bowel obstruction.

Although clinical research on ipamorelin is limited, research in animal models has shown its potential for treating childhood GH deficiency and other growth disorders.

Ipamorelin is a ghrelin receptor agonist, and thus mimics the effects of the naturally-occurring hormone ghrelin, which is responsible for regulating GH secretion. Ghrelin is also associated with physiological processes such as hunger and metabolism.

Ipamorelin's binding to the ghrelin receptor in the brain triggers a series of downstream effects, including the direct stimulation of the cells in the pituitary gland, causing them to release GH and thus result in a rise in GH levels throughout the body. The role of ipamorelin in triggering GH release has implications for a range of physiological processes, including metabolism, muscle growth, and bone formation.

A seminal study found that ipamorelin, unlike many other GH secretagogues and rHGH treatment itself, does not elevate the plasma levels of other hormones in the body, such as the stress hormone cortisol. In other words, ipamorelin acts by selectively increasing GH, similar to the action of growth hormone-releasing hormone (GHRH).

This targeted selectivity of ipamorelin is seen as advantageous when investigating its potential therapeutic uses. Researchers have called for closer investigation into the selectivity of ipamorelin as a targeted treatment of growth-related impairments that does not induce additional hormonal changes.

· Ipamorelin and Gastric Motility

In clinical trials, researchers examined the impact of ipamorelin on patients with postoperative ileus, a relatively common post-surgery condition where patients experience difficulty in eating and digesting solid foods. The study found that ipamorelin drastically shortened the time it took for the patients to be able to take their first meal, by about 12 hours.

· Ipamorelin and Muscle Strength

Ipamorelin may have a protective effect against loss of muscle strength, especially in cases where medications like glucocorticoids that lead to muscle atrophy are taken.

Growth hormone itself is known to possess anabolic properties, working to increase muscle strength by enhancing muscle mass. While the direct impact of ipamorelin on muscle strength has not yet been studied, the peptide's ability to stimulate GH is widely believed to enhance muscle performance in competitive athletics and muscle function in the elderly subjects.

· Ipamorelin and GH Deficiency

An early study looked into the impact of a related synthetic peptide and ipamorelin predecessor, GHRP-2, on GH-deficient children. Six children with GH deficiency were administered subcutaneous injections of GHRP-2 for four successive periods of two months, with GHRH added to the fourth period of administration. While GHRP-2 was successful in promoting nocturnal GH secretion and increased growth velocity in the treatment phase, the authors called for the development of a treatment with a longer duration of action .

While there is clear benefit to the use of ipamorelin as a treatment of GHD, given its selectivity for the ghrelin receptor, research on this use is still needed.

Ipamorelin has not been approved for medical use and there are no established guidelines for determining a safe and effective dose of this peptide. Research on the peptide is strictly limited to laboratory experimentation, unless research in test subjects is authorized.

However, researchers may be interested to know how ipamorelin may be dosed in future experiments.

Based on the available literature, here are some notes regarding ipamorelin administration and dosage:

• Ipamorelin is most commonly delivered via subcutaneous or intramuscular injection, the methods considered most effective.

• Treatment with ipamorelin has been shown to be dose-dependent and doses will vary depending on the desired therapeutic outcome.

• A common dosing protocol used by researchers is 200mcg to 500mcg of ipamorelin per day via subcutaneous injection. Doses greater than 200mcg may be split into two to three injections, administered at different times of day.

• Researchers are encouraged to begin with a low dose, before gradually increasing the daily ipamorelin dosage.

• Current research does not generally support the long-term use of ipamorelin in subjects, for periods exceeding 12 weeks.

Product Name	INN, ipamorelin
CAS	170851-70-4
Molar mass	711.868
MF	C38H49N9O5
Capacity/Bottle	2mg/vial
Shape	Lyophilized powder

 

Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885

 

No, Ipamorelin is not a steroid. It is a synthetic peptide classified as a growth hormone secretagogue. Ipamorelin belongs to a class of compounds known as growth hormone-releasing peptides (GHRPs). These peptides stimulate the release of growth hormone (GH) from the pituitary gland in the body.

Ipamorelin works by binding to specific receptors in the pituitary gland, which triggers the release of GH. Unlike steroids, which are synthetic versions of hormones like testosterone, Ipamorelin does not contain hormones itself. Instead, it indirectly influences the body's natural production of growth hormone.

Ipamorelin and other GHRPs are sometimes used for various purposes, including increasing GH levels, which can have benefits for muscle growth, fat loss, and potentially anti-aging effects. However, their use is typically regulated and requires a prescription from a healthcare provider. They are not classified as steroids and do not have the same properties or mechanisms of action as anabolic steroids.

 

Hot Tags: Ipamorelin CAS:170851-70-4, China Ipamorelin CAS:170851-70-4 manufacturers, suppliers, factory